Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation

New England Journal of Medicine

Volumn 366, Issue 7, 2012, Pages 586-589

  Gill, John S ^a,c   Tonelli, Marcello ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Interdisciplinary Chronic Disease Collaboration   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FUNDING; GRAFT RECIPIENT; HEALTH CARE POLICY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MEDICAL FEE; MEDICARE; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE ALLOCATION; SHORT SURVEY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84857131378     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1114394     Document Type: Article

References (5)

1. Kasiske BL, Cohen D, Lucey MR, Neylan JF. Payment for immunosuppression after organ transplantation. JAMA 2000;283:2445-50. (Pubitemid 30257550)
2. Evans RW, Applegate WH, Briscoe DM, et al. Cost-related immunosuppressive medication nonadherence among kidney transplant recipients. Clin J Am Soc Nephrol 2010;5:2323-8.
3. Woodward RS, Page TF, Soares R, Schnitzler MA, Lentine KL, Brennan DC. Income-related disparities in kidney transplant graft failures are eliminated by Medicare's immunosuppression coverage. Am J Transplant 2008;8:2636-46.
4. Page TF, Woodward RS. Cost-effectiveness of Medicare's coverage of immunosuppression medications for kidney transplant recipients. Expert Rev Pharmacoecon Outcomes Res 2009;9:435-44.
5. Becker BN. A conflict of responsibility: no patient left behind. Clin J Am Soc Nephrol 2010;5:744-5.